Effect of Atorvastatin on Carotid Intima Media Thickness
Essential Hypertension, Hypercholesterolemia
About this trial
This is an interventional treatment trial for Essential Hypertension focused on measuring arterial hypertension, statin, carotid artery intima-media thickness
Eligibility Criteria
Inclusion Criteria:
• Patients aged between 45 and 85 years
- blood pressure ≥ 140/90 mmHg with one antihypertensive drug or 150/100 mHg for untreated patients
- plasma LDL-cholesterol concentrations > 4.1 mmol/L without hypolipidemic drugs within the last 6 months
- at least one additional cardiovascular risk factor apart of arterial hypertension
- minimal thickness of intima media complex at least 0,8 mm.
Exclusion Criteria:
- premenopausal females with potential for pregnancy
- angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker therapy in the previous 3 months,
- initiation or change in dose of statin therapy within previous 3 months
- anticipated change in lipid lowering therapy
- acute coronary or cerebrovascular event within 2 months
- glomerular filtration rate < 30 ml/min
- previous history of side effects to RAAS inhibitors and Ca channel blocking agents
- inability to give informed consent
- inability to undergo carotid ultrasound examination
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Perindopril/Amlodipine arm
Perindopril/Amlodipine/Atorvastatin arm
Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study. Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia.
Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.